Tumor Microenvironment-Adaptive Nanoplatform Synergistically Enhances Cascaded Chemodynamic Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36254272.
- Also identified by DOI 10.1016/j.bioactmat.2022.09.025 and PMC identifier 9550605.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemodynamic therapy (CDT), a noninvasive strategy, has emerged as a promising alternative to conventional chemotherapy for treating tumors. However, its therapeutic effect is limited by the amount of H<sub>2</sub>O<sub>2</sub>, pH value, the hypoxic environment of tumors, and it has suboptimal tumor-targeting ability. In this study, tumor cell membrane-camouflaged mesoporous Fe<sub>3</sub>O<sub>4</sub> nanoparticles loaded with perfluoropentane (PFP) and glucose oxidase (GOx) are used as a tumor microenvironment-adaptive nanoplatform (M-mFeP@O<sub>2</sub>-G), which synergistically enhances the antitumor effect of CDT. Mesoporous Fe<sub>3</sub>O<sub>4</sub> nanoparticles are selected as inducers for photothermal and Fenton reactions and as nanocarriers. GOx depletes glucose within tumor cells for starving the cells, while producing H<sub>2</sub>O<sub>2</sub> for subsequent ·OH generation. Moreover, PFP, which can carry O<sub>2</sub>, relieves hypoxia in tumor cells and provides O<sub>2</sub> for the cascade reaction. Finally, the nanoparticles are camouflaged with osteosarcoma cell membranes, endowing the nanoparticles with homologous targeting and immune escape abilities. Both <i>in vivo</i> and <i>in vitro</i> evaluations reveal high synergistic therapeutic efficacy of M-mFeP@O<sub>2</sub>-G, with a desirable tumor-inhibition rate (90.50%), which indicates the great potential of this platform for clinical treating cancer.